Why the study?
Effective therapeutic approaches for cardiac fibrosis are lacking, and questions remain regarding the mechanisms whereby emodin impacts fibrosis.
Key points are not available for this paper at this time.
Population
Cardiac fibroblasts treated with TGF-β1
Comparison
Emodin vs control/untreated in TGF-β1-stimulated cells
Design
In vitro experimental study
Supports preclinical testing of emodin in cardiac fibrosis; leaves open clinical translation from in vitro and animal data.
Cardiac fibrosis accompanies a number of pathological conditions and results in altered myocardial structure, biomechanical properties and function. The signaling networks leading to fibrosis are complex, contributing to the general lack of progress in identifying effective therapeutic approaches to prevent or reverse this condition. Several studies have shown protective effects of emodin, a plant-derived anthraquinone, in animal models of fibrosis. A number of questions remain regarding the mechanisms whereby emodin impacts fibrosis. TGF-β1 is a potent stimulus of fibrosis and fibroblast activation. In the present study, experiments were performed to evaluate the effects of emodin on activation and function of cardiac fibroblasts following treatment with TGF-β1. We demonstrate that emodin attenuates TGF-β1-induced fibroblast activation and collagen accumulation in vitro . Emodin also inhibits activation of several canonical (SMAD2/3) and non-canonical (Erk1/2) TGF-β signaling pathways, while activating the p38 pathway. These results suggest that emodin may provide an effective therapeutic agent for fibrosis that functions via specific TGF-β signaling pathways.
No takes yet. Share an insight, caveat, or question.
Carver et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: